In addition, HMGCR inhibitor simvastatin could also robustly enhances cancer vaccinations and synergizes with anti-PD-1 antibodies, which shows the broad therapeutic perspectives of drugs targeting cholesterol pathways in combination with other anti-tumor treatments (63). Here, HMGCR is linked to neoplasm.